FDA approves quarterly siRNA for myasthenia gravis - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves quarterly siRNA for myasthenia gravis

  • By

  • Mouj Hijazi

  • November 19, 2026

  • 2 min

Share

Clinical Scorecard: FDA approves quarterly siRNA for myasthenia gravis

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: FDA approves quarterly siRNA for myasthenia gravis
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPopulation described in the source article.
Care SettingCemdisiran is administered subcutaneously by a health care provider every 3 months and is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program.

Key Highlights

  • Cemdisiran (Livsayis) is the first siRNA therapy approved for gMG and the only FDA-approved gMG treatment with quarterly subcutaneous dosing, according to the company.
  • In the phase 3 NIMBLE trial primary analysis population, the week-24 MG-ADL score improved by 4.5 points with cemdisiran and 2.2 points with placebo; the placebo-adjusted difference was 2.3 points.
  • At least a 3-point MG-ADL improvement occurred in 76.6% of cemdisiran-treated patients and 44.1% of placebo-treated patients.
  • QMG scores improved by 4.2 points with cemdisiran and 1.5 points with placebo; the placebo-adjusted improvement was 2.8 points. At least a 5-point QMG improvement occurred in 48.4% and 19% of patients, respectively.
  • Regeneron reported improvements beginning within 2 weeks and maintained through 24 weeks.
  • The prescribing information includes a boxed warning for serious meningococcal infections and requires access through a restricted REMS program.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • The prescribing information warns about serious meningococcal infection and other serious infections associated with reduced complement activity.
      • Reported adverse reactions included injection-site reactions, viral infections, and urinary tract infections.

      Risks

        Patient & Prescribing Data

        Cemdisiran is given at 567 mg subcutaneously every 3 months by a health care provider. FDA approval was supported by the randomized, double-blind, placebo-controlled phase 3 NIMBLE trial of 284 patients, which evaluated cemdisiran alone, a C5-inhibiting monoclonal antibody alone, the combination, or placebo.

        Clinical Best Practices

        • Confirm meningococcal vaccination is up to date and given at least 2 weeks before treatment when possible.
        • Use antibacterial prophylaxis when urgent treatment is required and the patient is not up to date with meningococcal vaccination.
        • Follow the restricted REMS program and do not initiate treatment during an unresolved serious Neisseria meningitidis infection.

        Related Resources & Content

        Original Source(s)

        Related Content